Table 1.

Characteristics of the patients with NSCLC and their response to anti-PD-1 or anti-PD-L1 treatments

CaseHistologyAgeSexSmoking statusOncogene mutationsDrugB2M/HLA-ICTLCombinedResponse
P7LUAD59MSmokerWTATEZOStrong/StrongStrongHighCR
P4LSCC78MSmokerWTATEZOStrong/StrongStrongHighPR
P13LUAD58FSmokerWTATEZOWeak/WeakWeakModeratePR
P8LNEC76MSmokerNAATEZOWeak/WeakWeakModeratePR
P9LSCC78MSmokerNAATEZONegative/NegativeNegativeNegativePR
P15LUAD63MSmokerRETNIVOWeak/WeakNegativeNegativePR
P12LUAD67FSmokerBRAFATEZOStrong/StrongStrongHighSD
P3LUAD58FNonsmokerRETATEZOStrong/StrongStrongHighSD
P5LSCC61MSmokerWTATEZOWeak/WeakStrongHighSD
P1LUAD53MSmokerKRASNIVOWeak/WeakNegativeNegativeSD
P2LSCC57MSmokerWTATEZONegative/NegativeNegativeNegativeSD
P14LUAD60FNonsmokerEGFRNIVOStrong/StrongStrongHighPD
P6LSCC54MSmokerNAATEZOStrong/StrongStrongHighPD
P10LSCC69MSmokerWTPEMBRONegative/NegativeNegativeNegativePD
P11LUAD47FSmokerWTPEMBRONegative/NegativeNegativeNegativePD
  • NOTE: The type of treatment and the levels of B2M and HLA-I immunostaining and CTL intratumoral infiltration are also specified. The “combined” column provides arbitrary values summarizing the data concerning B2M/HLA-I immunostaining and CTL infiltration, as indicated.

  • Abbreviations: ATEZO, atezolizumab; CR, complete response; LNEC, lung neuroendocrine carcinoma; NIVO, nivolumab; PD, progressive disease; PEMBRO, pembrolizumab; PR, partial response; SD, stable disease.